Protagonist Therapeutics, Inc.
PTGX
Pozycja w akcjach
#2247
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Cena akcji
$138.50
Kapitalizacja rynkowa
$8.96B
Zmiana (1 dzień)
3.02%
Zmiana (1 rok)
80.53%
Kraj
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategoria
Healthcare
Zyski dla Protagonist Therapeutics, Inc. (PTGX)
Zyski w Jun 2026 TTM: $84.34M
Według najnowszych raportów finansowych Protagonist Therapeutics, Inc., obecny zysk firmy wynosi $84.34M. W roku 2023 firma osiągnęła zysk w wysokości $-78.96M, wzrost w porównaniu do zysku z roku 2022, który wynosił $-127.39M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Protagonist Therapeutics, Inc. od 2014 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $84.34M | -69.82% |
| 2024 | $279.41M | -453.88% |
| 2023 | $-78.96M | -38.02% |
| 2022 | $-127.39M | 1.47% |
| 2021 | $-125.55M | 93.62% |
| 2020 | $-64.85M | -16.74% |
| 2019 | $-77.88M | 96.05% |
| 2018 | $-39.72M | 7.48% |
| 2017 | $-36.96M | -0.59% |
| 2016 | $-37.18M | 150.22% |
| 2015 | $-14.86M | 34.19% |
| 2014 | $-11.07M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | 6,154.48% |
US
|
|
| $-3.09B | -3,760.27% |
US
|
|
| $-4.02B | -4,862.02% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 2,212.90% |
NL
|
